A campaign to position Worcester as a center for biopharmaceutical drug-making is scheduled to kick off Thursday with a press conference at the Massachusetts Biotechnology Council and the release of a report suggesting Boston area companies should capitalize on the manufacturing legacy of central Massachusetts rather than send production out of state.
“The robust growth of the state’s drug discovery sector hasn’t translated into manufacturing,” said Kevin O’Sullivan, president of Massachusetts Biomedical Initiatives, an economic development group that cosponsored the report. “A lot of biopharma manufacturing is being shipped to North Carolina or elsewhere. My question is, why isn't it coming here?”
An industry shift from large-scale production of blockbuster drugs to smaller runs of protein-based biologics for specific patient populations could make the former factory buildings dotting Worcester ideal manufacturing sites, according to the report. Full story for BostonGlobe.com subscribers.